Evaluation of the clinical efficiency of tocilizumab therapy, by using DAS 28, SDAI, CDAI indices and new 2011 EULAR/ACR remission criteria in patients with rheumatoid arthritis
Objective: to evaluate the clinical efficiency of tocilizumab (TCZ) from the DAS 28, SDAI, and CDAI indices and to estimate remission rates from the European League Against Rheumatism (EULAR) criteria, and the new remission criteria proposed by the EULAR and the American College of Rheumatology (ACR...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2012-04-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/1162 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849688783226667008 |
|---|---|
| author | Anastasia Sergeyevna Avdeyeva E Yu Panasyuk E N Aleksandrova E L Nasonov |
| author_facet | Anastasia Sergeyevna Avdeyeva E Yu Panasyuk E N Aleksandrova E L Nasonov |
| author_sort | Anastasia Sergeyevna Avdeyeva |
| collection | DOAJ |
| description | Objective: to evaluate the clinical efficiency of tocilizumab (TCZ) from the DAS 28, SDAI, and CDAI indices and to estimate remission rates from the European League Against Rheumatism (EULAR) criteria, and the new remission criteria proposed by the EULAR and the American College of Rheumatology (ACR) in 2011. Subjects and methods. Forty-two patients with rheumatoid arthritis (RA) who had received 6 infusions of TCZ in an intravenous dose of 8 mg/kg at a 4-week interval during stable therapy with disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids were examined. The EULAR criteria based on changes in the DAS 28 index and the SDAI and CDAI activity indices were used to evaluate the efficiency of TCZ therapy. Disease remission was assessed by the EULAR criteria and the new 2011 EULAR/ACR remission criteria. Results. The baseline values (median and interquartile range: 25-75th percentiles) were 6.44 (5.87-7.04) for DAS 28; 45 (36.2-57) for SDAI; and 41.5 (32-53) for CDAI. At week 2 of TCZ therapy, there was a reduction in the levels of DAS 28 to 4.86 (4.28-5.29) and at week 4, there were decreases in SDAI to 22.6 (19.4-29.3) and CDAI to 21.9 (19.3-30), which remained until week 24 (p < 0.01). By week 24 of TCZ therapy, according to the EULAR criteria, 35 and 7 patients were observed to have good and moderate effects, respectively. By week 24, 30 (71%), 13 (31%), and 14 (33%) patients achieved remission according to DAS 28, SDAI, and CDAI, respectively; low DAS 28 (2.6-3.2), SDAI (3.3-11), and CDAI (2.8-10) disease activity was observed in 5 (12%), 21 (50%), and 20 (47.6%) patients, respectively; high SDAI and CDAI activities remained in 2 (4.8%) patients. Remission was observed in 10 (24%) patients according to the 2011 criteria. Conclusion. The obtained results of the 24-week study suggest that TCZ therapy is highly effective according to the changes in DAS 28, SDAI, CDAI activity indices and to the new 2011 EULAR/ACR remission criteria in severe RA resistant to the standard treatment with DMARDs. |
| format | Article |
| id | doaj-art-3135ea0df91743cab1647cd8e446003d |
| institution | DOAJ |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| publishDate | 2012-04-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj-art-3135ea0df91743cab1647cd8e446003d2025-08-20T03:21:51ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922012-04-01502202410.14412/1995-4484-2012-12681102Evaluation of the clinical efficiency of tocilizumab therapy, by using DAS 28, SDAI, CDAI indices and new 2011 EULAR/ACR remission criteria in patients with rheumatoid arthritisAnastasia Sergeyevna AvdeyevaE Yu PanasyukE N AleksandrovaE L NasonovObjective: to evaluate the clinical efficiency of tocilizumab (TCZ) from the DAS 28, SDAI, and CDAI indices and to estimate remission rates from the European League Against Rheumatism (EULAR) criteria, and the new remission criteria proposed by the EULAR and the American College of Rheumatology (ACR) in 2011. Subjects and methods. Forty-two patients with rheumatoid arthritis (RA) who had received 6 infusions of TCZ in an intravenous dose of 8 mg/kg at a 4-week interval during stable therapy with disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids were examined. The EULAR criteria based on changes in the DAS 28 index and the SDAI and CDAI activity indices were used to evaluate the efficiency of TCZ therapy. Disease remission was assessed by the EULAR criteria and the new 2011 EULAR/ACR remission criteria. Results. The baseline values (median and interquartile range: 25-75th percentiles) were 6.44 (5.87-7.04) for DAS 28; 45 (36.2-57) for SDAI; and 41.5 (32-53) for CDAI. At week 2 of TCZ therapy, there was a reduction in the levels of DAS 28 to 4.86 (4.28-5.29) and at week 4, there were decreases in SDAI to 22.6 (19.4-29.3) and CDAI to 21.9 (19.3-30), which remained until week 24 (p < 0.01). By week 24 of TCZ therapy, according to the EULAR criteria, 35 and 7 patients were observed to have good and moderate effects, respectively. By week 24, 30 (71%), 13 (31%), and 14 (33%) patients achieved remission according to DAS 28, SDAI, and CDAI, respectively; low DAS 28 (2.6-3.2), SDAI (3.3-11), and CDAI (2.8-10) disease activity was observed in 5 (12%), 21 (50%), and 20 (47.6%) patients, respectively; high SDAI and CDAI activities remained in 2 (4.8%) patients. Remission was observed in 10 (24%) patients according to the 2011 criteria. Conclusion. The obtained results of the 24-week study suggest that TCZ therapy is highly effective according to the changes in DAS 28, SDAI, CDAI activity indices and to the new 2011 EULAR/ACR remission criteria in severe RA resistant to the standard treatment with DMARDs.https://rsp.mediar-press.net/rsp/article/view/1162das 28sdaicdairheumatoid arthritistocilizumabdas 28sdaicdairemission |
| spellingShingle | Anastasia Sergeyevna Avdeyeva E Yu Panasyuk E N Aleksandrova E L Nasonov Evaluation of the clinical efficiency of tocilizumab therapy, by using DAS 28, SDAI, CDAI indices and new 2011 EULAR/ACR remission criteria in patients with rheumatoid arthritis Научно-практическая ревматология das 28 sdai cdai rheumatoid arthritis tocilizumab das 28 sdai cdai remission |
| title | Evaluation of the clinical efficiency of tocilizumab therapy, by using DAS 28, SDAI, CDAI indices and new 2011 EULAR/ACR remission criteria in patients with rheumatoid arthritis |
| title_full | Evaluation of the clinical efficiency of tocilizumab therapy, by using DAS 28, SDAI, CDAI indices and new 2011 EULAR/ACR remission criteria in patients with rheumatoid arthritis |
| title_fullStr | Evaluation of the clinical efficiency of tocilizumab therapy, by using DAS 28, SDAI, CDAI indices and new 2011 EULAR/ACR remission criteria in patients with rheumatoid arthritis |
| title_full_unstemmed | Evaluation of the clinical efficiency of tocilizumab therapy, by using DAS 28, SDAI, CDAI indices and new 2011 EULAR/ACR remission criteria in patients with rheumatoid arthritis |
| title_short | Evaluation of the clinical efficiency of tocilizumab therapy, by using DAS 28, SDAI, CDAI indices and new 2011 EULAR/ACR remission criteria in patients with rheumatoid arthritis |
| title_sort | evaluation of the clinical efficiency of tocilizumab therapy by using das 28 sdai cdai indices and new 2011 eular acr remission criteria in patients with rheumatoid arthritis |
| topic | das 28 sdai cdai rheumatoid arthritis tocilizumab das 28 sdai cdai remission |
| url | https://rsp.mediar-press.net/rsp/article/view/1162 |
| work_keys_str_mv | AT anastasiasergeyevnaavdeyeva evaluationoftheclinicalefficiencyoftocilizumabtherapybyusingdas28sdaicdaiindicesandnew2011eularacrremissioncriteriainpatientswithrheumatoidarthritis AT eyupanasyuk evaluationoftheclinicalefficiencyoftocilizumabtherapybyusingdas28sdaicdaiindicesandnew2011eularacrremissioncriteriainpatientswithrheumatoidarthritis AT enaleksandrova evaluationoftheclinicalefficiencyoftocilizumabtherapybyusingdas28sdaicdaiindicesandnew2011eularacrremissioncriteriainpatientswithrheumatoidarthritis AT elnasonov evaluationoftheclinicalefficiencyoftocilizumabtherapybyusingdas28sdaicdaiindicesandnew2011eularacrremissioncriteriainpatientswithrheumatoidarthritis |